What Exactly Are Wixela and Advair?
Wixela Inhub is a generic version of Advair Diskus, both fixed-dose combination inhalers containing fluticasone propionate (an inhaled corticosteroid) and salmeterol (a long-acting beta2-agonist, or LABA). They treat asthma and COPD by reducing inflammation and relaxing airway muscles.[1]
Key Difference: Generic vs. Brand-Name
Advair Diskus is the branded product from GlaxoSmithKline (GSK), first approved by the FDA in 2000. Wixela Inhub, made by Mylan (now part of Viatris), gained FDA approval in 2019 as the first interchangeable generic for Advair Diskus 100/50, 250/50, and 500/50 mcg strengths. This means Wixela matches Advair's active ingredients, dosage, strength, route, and performance, allowing pharmacists to substitute it without prescriber approval in most states.[1][2]
Do They Work the Same Way?
Yes, clinically. Both deliver the same drug amounts per inhalation via dry powder inhalers. FDA interchangeability requires bioequivalence studies showing identical absorption and effects. Real-world data shows no significant differences in lung function improvement or exacerbation rates for asthma or COPD patients switching from Advair.[3]
Why Choose One Over the Other?
Cost drives the choice. Advair lists around $400-600 for a 30-day supply without insurance, while Wixela costs $100-200. Insurance often favors generics, but some patients report minor taste or device feel differences, though these don't affect efficacy.[4]
Availability and Patent Timeline
GSK's patents on Advair Diskus expired in 2019, enabling Wixela's launch after FDA approval. No major patent disputes remain; multiple generics (e.g., from Prasco, Sandoz) now compete. Check DrugPatentWatch.com for expiration details on remaining formulation patents.[5]
Switching from Advair: What Patients Experience
Patients report smooth transitions, with studies showing 90%+ satisfaction and stable control. Rinse mouth after use for both to avoid thrush. No dose adjustments needed.[3][6]
Are There Side Effects Differences?
Side effects match: thrush, hoarseness, pneumonia risk (higher in COPD), fast heartbeat, or tremors. Black-box warnings apply equally for asthma-related death risk with LABAs without steroids. Report issues to FDA MedWatch.[1]
Sources:
[1] FDA: Advair Diskus Label
[2] FDA: Wixela Inhub Approval
[3] Journal of Allergy and Clinical Immunology: Generic Interchangeability Study
[4] GoodRx: Pricing Comparison
[5] DrugPatentWatch.com: Advair Patents
[6] Respiratory Medicine: Patient Switch Data